Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether or not Recombinant DNA-based hyaluronidase (RDNAH/Hylenex recombinant), is safe and effective for dissolving hyaluronic acid (HA) dermal fillers.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02654522
Study type Interventional
Source Steve Yoelin M.D. Medical Associates, Inc.
Contact
Status Completed
Phase Phase 1
Start date January 2016
Completion date February 2016

See also
  Status Clinical Trial Phase
Completed NCT04546516 - Safety and Efficacy of the HA-based Dermal Fillers HYAcorp Lips and Face
Completed NCT04546152 - Safety and Efficacy of the HA-based Dermal Fillers HYAPROF® SOFT and HYAPROF® BALANCE
Active, not recruiting NCT05694286 - A Prospective Evaluation of Infraorbital Filler Injection N/A
Completed NCT05822778 - Formaderm (Hyaluronic Acid) for Facial Soft Tissue Augmentation N/A
Completed NCT05294562 - China Post-Market Clinical Follow-up of FACILLE®
Completed NCT04569045 - Evaluate the Safety and Effectiveness of Sodium Hyaluronate When Used for the Correction of Nasolabial Folds N/A
Completed NCT04622085 - The Evaluation of the Safety and Effectiveness of ANIMERS Chiara LA and JUVÉDERM VOLUMA® for Aging Mid-Face N/A
Completed NCT04599335 - The Evaluation of the Safety and Effectiveness of a Novel Gel-type Sodium Hyaluronate for the Correction of Aging Mid-face N/A
Recruiting NCT05853224 - An Interventional Study to Evaluate the Safety and Performance of Crosslinked Hyaluronic Acid Hydrogel N/A